MediWound Ltd.
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company's proteolytic enzyme technology. NexoBrid is a topically-applied product that removes eschar in approximately four hours without harming the surrounding healthy tissues. The Company offers NexoBrid in Europe and Israel. NexoBrid has been investigated in over 550 patients across approximately 15 countries and over four continents in approximately six completed Phase II and Phase III clinical studies.
News
(NetworkNewsWire) When Christopher Columbus introduced the pineapple to Europe in the late fifteenth century, he undoubtedly would have had no idea that extracts from the plant could be used to treat severe thermal burns. Yet, 500 years later, a next-generation proteolytic enzyme platform for wound debridement, NexoBrid, derived from pineapples, has been developed by MediWound Ltd.
MediWound Ltd. (NASDAQ:MDWD) is a biopharmaceutical company in the business of developing, manufacturing, and globally commercializing products that treat severe burns and wounds. In 2012, MediWound's innovative drug, NexoBrid(TM), a burn and wound eschar removal agent, was approved by the European Medicines Agency (EMA) via a centralized procedure. The drug was given orphan indication for removal of dead and damaged skin in adults with burns that are deep partial and full thickness thermal burns.
###
1,669 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 5) (Last 30 Days: 19) (Since Published: 1669)
